Adjuvant Radiation Therapy for Single Brain Metastasis

Introduction to Adjuvant Radiation Therapy

• The American Society of Clinical Oncology (ASCO) recommends postoperative radiotherapy for most patients with brain metastases who undergo surgical resection, to reduce the risk of local recurrence, regardless of imaging uncertainty 1, 2
• The ASCO guidelines (2022) explicitly recommend postoperative radiotherapy for patients with brain metastases who undergo surgical resection, with a strong evidence base 1, 2

Rationale for Postoperative Radiation Therapy

• Multiple guidelines, including those from ASCO, consistently recommend surgery with postoperative radiation as a treatment option for single brain metastasis in patients with favorable prognosis 1, 2, 3, 4, 5, 6
• Historical randomized trials demonstrate that adding whole-brain radiotherapy to surgery for solitary brain metastasis improved local and distant brain control, though not overall survival 7

Radiation Modality Selection

• The American Society of Clinical Oncology (ASCO) prefers stereotactic radiosurgery (SRS) to the resection bed when feasible, as it minimizes neurocognitive toxicity compared to whole-brain radiotherapy (WBRT) 1, 2
• The European Society for Medical Oncology (ESMO) and the European Society of Oncology (ESO) note that if surgery/radiosurgery is performed, it may be followed by WBRT, but this should be discussed in detail with the patient, balancing longer duration of intracranial disease control against the risk of neurocognitive effects 8, 9

Special Considerations for Breast Cancer Patients

• Breast cancer patients with brain metastases, particularly those with HER2-positive disease, can have extended survival, making consideration of long-term neurocognitive toxicity particularly important 1, 8, 9
• The ESO-ESMO consensus (2018) achieved 89% consensus on preferring stereotactic RT over WBRT for HER2-positive breast cancer patients with limited brain metastases 8, 9

Monitoring After Treatment

• The Society for Neuro-Oncology recommends brain MRIs every 2-3 months for the first 1-2 years after initial treatment, with earlier scans prompted by new or worsening symptoms 10
• Advanced imaging techniques (perfusion MRI, PET) can help differentiate radiation necrosis from tumor progression if enhancement develops at the treated site 10

Common Pitfalls to Avoid

• The American Society of Clinical Oncology (ASCO) advises against withholding postoperative radiation simply because imaging is unclear about residual disease, as microscopic residual disease is common after resection and cannot be reliably excluded by imaging alone 1, 2
• ASCO also advises against automatically using whole-brain radiotherapy in this setting, as modern evidence supports focal radiation (SRS/HSRT) to the resection bed for single metastases, preserving neurocognitive function without compromising local control 1, 2, 7